Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors

• ClinicalTrials.gov Identifier: NCT00075387
• Recruitment Status: Recruiting
• First Posted: January 12, 2004
• Last Update Posted: November 10, 2020
• Sponsor: OHSU Knight Cancer Institute
• Collaborator: Oregon Health and Science University
• Information provided by (Responsible Party): Edward Neuwelt, OHSU Knight Cancer Institute

Study Description

Brief Summary:

This randomized phase II trial studies how well giving combination chemotherapy with or without sodium thiosulfate works in preventing low platelet count while treating patients with malignant brain tumors. Drugs used in chemotherapy, such as carboplatin, cyclophosphamide, and etoposide phosphate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Sodium thiosulfate may prevent low platelet counts in patients receiving chemotherapy. It is not yet known whether combination chemotherapy is more effective with or without sodium thiosulfate in preventing low platelet count during treatment for brain tumors.

Condition or disease	Intervention/treatment	Phase
Malignant Glioma	Drug: Carboplatin; Drug: Cyclophosphamide; Drug: Etoposide Phosphate; Other: Quality-of-Life Assessment; Drug: Sodium Thiosulfate	Phase 2

Detailed Description:

PRIMARY OBJECTIVE:

I. Determine the effect of delayed administration of sodium thiosulfate on the rates of platelet toxicity (i.e. platelet count less than 20,000), in subjects with high-grade glioma undergoing treatment with carboplatin, cyclophosphamide and etoposide/etoposide phosphate.

SECONDARY OBJECTIVES:

I. Assess tumor response in subjects with high-grade glioma undergoing treatment with carboplatin, cyclophosphamide and etoposide/etoposide phosphate, with or without delayed sodium thiosulfate.

II. Assess the effect of delayed administration of sodium thiosulfate on granulocyte and erythrocyte counts, in subjects undergoing treatment with carboplatin, cyclophosphamide and etoposide/etoposide phosphate.

III. Assess hearing changes, if any, at the higher frequencies in the standard testing range (4000 and 8000 Hertz [Hz]), and at higher frequencies above standard testing (9000 to 16000 Hz).

IV. Assess quality of life in subjects undergoing treatment with carboplatin, cyclophosphamide and etoposide phosphate.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive cyclophosphamide intravenously (IV), etoposide phosphate IV, and carboplatin intra-arterially (IA) over 10 minutes on day 1.

ARM II: Patients receive cyclophosphamide IV, etoposide phosphate IV, and carboplatin IA as in Arm I. Patients also receive sodium thiosulfate IV over 15 minutes 4 and 8 hours after carboplatin.

In both arms, treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 60 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Single (Investigator)
• Primary Purpose: Treatment
• Official Title: Phase II Clinical Trial of Patients With High-Grade Glioma Treated With Intra-Arterial Carboplatin-Based Chemotherapy, Randomized to Treatment With or Without Delayed Intravenous Sodium Thiosulfate as a Potential Chemoprotectant Against Severe Thrombocytopenia
• Actual Study Start Date: March 7, 2003
• Estimated Primary Completion Date: April 30, 2022
• Estimated Study Completion Date: April 30, 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: Arm I (combination chemotherapy); Patients receive cyclophosphamide IV, etoposide phosphate IV, and carboplatin IA over 10 minutes. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.	Drug: Carboplatin; Given IA; Other Names: Blastocarb; Carboplat; Carboplatin Hexal; Carboplatino; Carboplatinum; Carbosin; Carbosol; Carbotec; CBDCA; Displata; Ercar; JM-8; Nealorin; Novoplatinum; Paraplatin; Paraplatin AQ; Paraplatine; Platinwas; Ribocarbo; Drug: Cyclophosphamide; Given IV; Other Names: (-)-Cyclophosphamide; 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate; Carloxan; Ciclofosfamida; Ciclofosfamide; Cicloxal; Clafen; Claphene; CP monohydrate; CTX; CYCLO-cell; Cycloblastin; Cycloblastine; Cyclophospham; Cyclophosphamid monohydrate; Cyclophosphamide Monohydrate; Cyclophosphamidum; Cyclophosphan; Cyclophosphane; Cyclophosphanum; Cyclostin; Cyclostine; Cytophosphan; Cytophosphane; Cytoxan; Fosfaseron; Genoxal; Genuxal; Ledoxina; Mitoxan; Neosar; Revimmune; Syklofosfamid; WR- 138719; Drug: Etoposide Phosphate; Given IV; Other Name: Etopophos; Other: Quality-of-Life Assessment; Ancillary studies; Other Name: Quality of Life Assessment
Experimental: Arm II (combination chemotherapy, sodium thiosulfate); Patients receive cyclophosphamide IV, etoposide phosphate IV, and carboplatin IA as in Arm I. Patients also receive sodium thiosulfate IV over 15 minutes 4 and 8 hours later. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.	Drug: Carboplatin; Given IA; Other Names: Blastocarb; Carboplat; Carboplatin Hexal; Carboplatino; Carboplatinum; Carbosin; Carbosol; Carbotec; CBDCA; Displata; Ercar; JM-8; Nealorin; Novoplatinum; Paraplatin; Paraplatin AQ; Paraplatine; Platinwas; Ribocarbo; Drug: Cyclophosphamide; Given IV; Other Names: (-)-Cyclophosphamide; 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate; Carloxan; Ciclofosfamida; Ciclofosfamide; Cicloxal; Clafen; Claphene; CP monohydrate; CTX; CYCLO-cell; Cycloblastin; Cycloblastine; Cyclophospham; Cyclophosphamid monohydrate; Cyclophosphamide Monohydrate; Cyclophosphamidum; Cyclophosphan; Cyclophosphane; Cyclophosphanum; Cyclostin; Cyclostine; Cytophosphan; Cytophosphane; Cytoxan; Fosfaseron; Genoxal; Genuxal; Ledoxina; Mitoxan; Neosar; Revimmune; Syklofosfamid; WR- 138719; Drug: Etoposide Phosphate; Given IV; Other Name: Etopophos; Other: Quality-of-Life Assessment; Ancillary studies; Other Name: Quality of Life Assessment; Drug: Sodium Thiosulfate; Given IV; Other Names: Cyanide Antidote Package; Disodium Thiosulfate; S-Hydril; Sodium Hyposulfate; Sodium Thiosulfate Pentahydrate; Sodium Thiosulphate; Sodothiol; Thiosulfate, Sodium, Pentahydrate; Thiosulfuric acid disodium salt

Outcome Measures

Primary Outcome Measures :

1. Rate of platelet toxicities (i.e. platelet count less than 20,000), graded according to the National Cancer Institute Common Toxicity Criteria version 3.0 [ Time Frame: Up to 4 weeks after completion of study treatment ]
   The Pearson chi-square test will be the primary test to compare rates.

Secondary Outcome Measures :

1. Number of dose reductions and transfusions due to platelet toxicity [ Time Frame: Up to 30 days after completion of study treatment ]
   Analyzed using generalized estimating equations and/or a generalized mixed model (for repeated measures analysis of variance) and the third using mixed model repeated measures analysis of variance model.
2. Tumor response (complete response + partial response + stable disease) assessed by neurologic exams, radiographic studies, and steroid dose [ Time Frame: Up to 10 years ]
   The Pearson chi-square test will be the primary test to compare rates. Comparisons of rates will use the Pearson Chi-square test and logistic regression to adjust for potential confounders.
3. Time to response [ Time Frame: Up to 10 years ]
   Descriptive summaries include Kaplan-Meier plots.
4. Time to disease progression [ Time Frame: Up to 10 years ]
   Comparisons of time to disease progression will use the log rank test and the Cox proportional hazards model to adjust for potential confounders.
5. Granulocyte count [ Time Frame: Up to 30 days after completion of study treatment ]
   The Pearson chi-square test will be the primary test to compare rates.
6. Erythrocyte counts [ Time Frame: Up to 30 days after completion of study treatment ]
   The Pearson chi-square test will be the primary test to compare rates.
7. Change in hearing levels, if any, at the higher frequencies in the standard testing range (4000 and 8000 Hz), and at higher frequencies above standard testing (9000 to 16000 Hz) based on American Speech-Language-Hearing Association criteria [ Time Frame: Baseline up to 30 days after completion of study treatment ]
   Descriptive summaries for hearing levels will include means by time and plots of hearing levels by patient over time. The analyses for hearing will include both a time to oto-toxicity (based on American Speech-Language-Hearing Association criteria) comparison using the log rank test and a repeated measure analysis of covariance of the actual hearing levels (with baseline hearing levels as the covariate). Separate analyses will be performed for each hearing frequency with no adjustment for multiple comparisons (as these analyses are descriptive in nature).
8. Quality of life assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 and Quality of Life Questionnaire-Brain Module-20 [ Time Frame: Up to 60 days after completion of study treatment ]
   Summarized by means over time and by plots of values over time for each patient. Quality of life data comparisons between the groups will use repeated measure analysis of covariance (baseline assessment as the covariate).

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Subjects with histologically confirmed high-grade glioma are eligible; diagnosis of high-grade glioma will be made on the basis of needle biopsy, open biopsy, or surgical resection
• Subjects may have had prior focal or systemic radiation or chemotherapy; at least 14 days must have elapsed since radiation treatment and 28 days since prior chemotherapy
• Performance status (Eastern Cooperative Oncology Group [ECOG]) must be less than or equal to 2 (Karnofsky greater than or equal to 50)
• White blood cell count >= 2.5 x 10^3/mm^3
• Absolute granulocyte count >= 1.2 x 10^3/mm^3
• Platelets >= 100 x 10^3/mm^3
• Creatinine < 1.8
• Bilirubin < 2.0
• Baseline aspartate aminotransferase (AST)/alanine aminotransferase (ALT) serum glutamic oxaloacetic transaminase (SGOT)/serum glutamate pyruvate transaminase (SGPT) must be < 2.5 x institutional upper limits of normal
• Subject (or legal guardian) must sign a written informed consent in accordance with institutional guidelines
• Sexually active women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; or abstinence) prior to study treatment and for the duration of study treatment; should a female become pregnant or suspect she is pregnant while participating in this study, she should inform the investigator

Exclusion Criteria:

• Subjects with rapidly progressing central nervous system (CNS) disease with associated neurological deterioration
• Subjects with uncontrolled (over the last 30 days) clinically significant confounding medical conditions such as congestive heart failure
• Subjects who are pregnant, have a positive serum human chorionic gonadotropin (hCG) or are lactating
• Subjects who have contraindications to carboplatin, cyclophosphamide, etoposide phosphate, or sodium thiosulfate

Contacts and Locations

Locations

United States, Minnesota

University of Minnesota/Masonic Cancer Center; Active, not recruiting

Minneapolis, Minnesota, United States, 55455

United States, Ohio

Cleveland Clinic Foundation; Active, not recruiting

Cleveland, Ohio, United States, 44195

United States, Oregon

OHSU Knight Cancer Institute; Recruiting

Portland, Oregon, United States, 97239

Contact: Edward A. Neuwelt 503-494-5626 neuwelte@ohsu.edu

Principal Investigator: Edward A. Neuwelt

Sponsors and Collaborators

OHSU Knight Cancer Institute

Oregon Health and Science University

Investigators

• Principal Investigator: Edward A Neuwelt; OHSU Knight Cancer Institute

More Information

• Responsible Party: Edward Neuwelt, Principal Investigator, OHSU Knight Cancer Institute
• ClinicalTrials.gov Identifier: NCT00075387
• Other Study ID Numbers: IRB00000922; NCI-2013-00781 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ); eIRB #922 ( Other Identifier: OHSU IRB ); ONC-02019-L ( Other Identifier: OHSU Knight Cancer Institute ); CR00023930 ( Other Identifier: OHSU IRB ); MR00041590 ( Other Identifier: OHSU IRB ); CR00021317 ( Other Identifier: OHSU IRB ); CR00018679 ( Other Identifier: OHSU IRB ); CR00022743 ( Other Identifier: OHSU IRB ); IRB00000922 ( Other Identifier: OHSU IRB )
• First Posted: January 12, 2004
• Last Update Posted: November 10, 2020
• Last Verified: November 2020

Additional relevant MeSH terms:

Glioma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue; Sodium thiosulfate; Cyclophosphamide; Carboplatin; Etoposide; Etoposide phosphate; Antidotes; Immunosuppressive Agents; Immunologic Factors; Physiological Effects of Drugs; Antirheumatic Agents; Antineoplastic Agents, Alkylating; Alkylating Agents; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Myeloablative Agonists; Antineoplastic Agents, Phytogenic; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Enzyme Inhibitors; Protective Agents; Antioxidants; Antitubercular Agents